首页 › 基金 › Paradigm Biocapital Advisors LP › BBIO
Paradigm Biocapital Advisors LP 对 BBIO 的持仓历史
BRIDGEBIO PHARMA INC · 医疗保健
Paradigm Biocapital Advisors LP 在 Q3 2026 的 13F 申报中披露持有 BBIO(BRIDGEBIO PHARMA INC)2,347,850 股,市值约 US$154.5M,约占其申报组合的 3.07%,在其申报持仓中市值排名第 12 位。 Paradigm Biocapital Advisors LP 最近 10 个申报季度中有 5 个季度披露了 BBIO 持仓,最早可追溯至 Q2 2024。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Paradigm Biocapital Advisors LP 对 BBIO 的持仓演变
Paradigm Biocapital Advisors LP 于 Q2 2024 首次披露 BBIO 持仓:1,089,492 股(约 US$27.6M)。 该持仓在 Q3 2026 达到峰值 2,347,850 股,市值约 US$154.5M。 在 5 次申报中,Paradigm Biocapital Advisors LP 0 次增持、1 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 2,347,850 股、市值约 US$154.5M。 持仓曾出现大幅变动:Q3 2025 减持约 29% (随后一个季度股价上涨 47%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2024 | 1.09M | $27.60M | 新进 |
| Q2 2025 | 965.76K | $41.70M | 新进 |
| Q3 2025 | 684.28K | $35.54M | 减持 |
| Q4 2025 | 684.28K | $52.34M | 持有 |
| Q3 2026 | 2.35M | $154.49M | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BBIO 与 13F 数据
BBIO(BRIDGEBIO PHARMA INC)属于医疗保健行业。我们追踪的基金中还有 41 只申报持有 BBIO,申报仓位最大的包括:Jupiter Topco LLC (US$1.05B), 骏利亨德森集团 (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 BBIO 的基金
- Jupiter Topco LLC 14.11M 股 · $1.05B · Q2 2026
- 骏利亨德森集团 13.18M 股 · $978.61M · Q1 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.25M 股 · $937.45M · Q3 2026
- 法拉龙资本管理 10.74M 股 · $800.14M · Q2 2026
- 维京环球投资 9.95M 股 · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M 股 · $741.02M · Q2 2026
- 双西格玛投资 3.66M 股 · $240.83M · Q3 2026
- Aisling Capital Management LP 3.09M 股 · $203.30M · Q3 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 104.89M 股 · $162.63M · Q3 2026
- SC US (TTGP), LTD. 1.86M 股 · $122.41M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.55M 股 · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M 股 · $102.27M · Q2 2026
更多关于 Paradigm Biocapital Advisors LP
常见问题
How long has Paradigm Biocapital Advisors LP held BBIO?
Paradigm Biocapital Advisors LP has disclosed BBIO holdings in 5 of the last 10 reported quarters, going back to Q2 2024.
What is Paradigm Biocapital Advisors LP's current position in BBIO?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 2.35M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $154.49M, representing 3.07% of its reported portfolio and ranking #12.
Has Paradigm Biocapital Advisors LP been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP newly opened its position in BBIO. The position peaked in Q3 2026 at 2.35M shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, 骏利亨德森集团, FARALLON CAPITAL MANAGEMENT, L.L.C., among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.